Some snippets from Briefing.
Peter, Are you able to reconcile the 2 ITMN comments? Bloomberg's comment leaves me baffled relative to the company's comments and actions. Thanks. Ian.
++++++++++++++
* 17:37 ET InterMune announces New England Journal of Medicine Publication (ITMN) 24.55 +0.22: Co announces the publication, in The New England Journal of Medicine, of previously presented results of the Co's initial Phase III trial (GIPF-001) evaluating the efficacy and safety of Actimmune for the treatment of patients with idiopathic pulmonary fibrosis. The findings from the trial form the basis for the Co's recently initiated, 600 patient, INSPIRE Trial, a randomized, double-blind, placebo-controlled pivotal phase III trial. The first patient was enrolled in this trial in Dec 2003. "The data from the GIPF-001 study are sufficient to warrant further investigation in a larger and longer clinical trial," said Talmadge E. King,Jr., M.D., Senior Author of the New England Journal of Medicine publication.
++++++++++++++++++++=
* 18:09 ET ITMN: Actimmune Ineffective for Lung Disease in Study : Bloomberg.com reports that InterMune Inc.'s (ITMN) Actimmune drug, the company's biggest product, isn't effective for most patients with a rare lung disease called pulmonary fibrosis, according to a study in the New England Journal of Medicine... see 17:37 update for related commentary.
+++++++++++++
18:10 ET After Hours Summary : After Hour market movers of note include: ... ITMN -6.4% (news that Actimmune drug ineffective for certain lung diseases), ... |
